EULAR Study Group on Hemochromatosis arthropathy

Study Group leader: Dr. Stephanie Finzel

Haemochromatosis arthropathy is a poorly researched and understood condition. Usually, diagnostics and treatment in HH focusses on prevention or reduction of organ damage, respectively. Commonly, HH-arthropathy is diagnosed with significant delay, and after joint damage already has occurred. Joint function however is of significant importance for the patients, since it impacts significantly on their quality of life and their capability of (social) participation.

The aim of this study group is to discuss many of the aspects of this arthropathy that we have all individually recognized, support patient associations by providing talks to patient groups (e.g. Birmingham, Belfast) and to develop EULAR classification criteria for haemochromatosis arthropathy.

Pre-work has already been carried out by the Haemochromatosis Arthropathy Research Initiative (HARI) with the support of the European Federation of Associations of Patients with Haemochromatosis (EFAPH).

Below you will find a list of the founding members of the group but we welcome, and anticipate, additional membership. Patients are very welcomed as well as the patient perspectives is very important.

AUSTRALIA
- Graeme Carroll, University of Notre Dame, Freemantle
- Helen Keen, Fiona Stanley Hospital and Royal Perth University, Perth

AUSTRIA
- Jochen Zwerina, Hanusch Hospital, Vienna (not active currently)

GERMANY:
- Stephanie Finzel, University of Freiburg, Freiburg
- Axel Braner, University of Frankfurt, Frankfurt/Main
- Reinhard Voll, University of Freiburg, Freiburg

FRANCE
- Pascal Guggenbuhl, Centre Hospitalier Universitaire de Rennes, Rennes
- Pierre Brissot, Hepatologist; Université de Rennes, Rennes

HUNGARY
- Gyorgy Nagy, Semmelweis University, Budapest

UK
- Patrick Kiely, St George’s University Hospitals, London

EFAPH
- Barbara Butzeck, patient representative, HVD Germany